Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsFRA:T06 7 EV-to-EBITDA is -7.15 as of Aug. 29, 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 733 Drug Manufacturers companies, VISEN Pharmaceuticals ranks worse than 136425.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, VISEN Pharmaceuticals's enterprise value is €206.81 Mil.
VISEN Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-28.92 Mil. Therefore, VISEN Pharmaceuticals's EV-to-EBITDA for today is -7.15.
The historical rank and industry rank for VISEN Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
FRA:T06'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.38 Med: -7.61 Max: -5.36
Current: -7.2
During the past 4 years, the highest EV-to-EBITDA of VISEN Pharmaceuticals was -5.36. The lowest was -12.38. And the median was -7.61.
FRA:T06's EV-to-EBITDA is ranked worse than 100% of 733
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs FRA:T06: -7.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VISEN Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
VISEN Pharmaceuticals's share price for today is €2.06.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.275.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
VISEN Pharmaceuticals EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for VISEN Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's EV-to-EBITDA falls into.
VISEN Pharmaceuticals's current Enterprise Value is €206.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-28.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals (FRA:T06) has a EV-to-EBITDA of -7.15 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on VISEN Pharmaceuticals. According to the industry distribution chart, VISEN Pharmaceuticals ranks #999999 out of 733 companies in the Drug Manufacturers industry.
Is VISEN Pharmaceuticals' EV-to-EBITDA too high?
VISEN Pharmaceuticals' current EV-to-EBITDA is -7.15. Based on the distribution chart, VISEN Pharmaceuticals ranks #999999 out of 733 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #999999 out of 733 companies for EV-to-EBITDA. This places VISEN Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on VISEN Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current EV-to-EBITDA is -7.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current EV-to-EBITDA of -7.15. The current EV-to-EBITDA is -7.15. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current EV-to-EBITDA is -7.15 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
